GLP-1 Safety
4 articles on GLP-1 Safety, written by Shotlee and medically reviewed for clinical accuracy.
Semaglutide and Pregnancy: Understanding New Risks and Weight Rebound
A recent national database study reveals significant obstetric risks associated with semaglutide exposure before and during pregnancy, highlighting the importance of the weight rebound effect.
7 min read
Novo Nordisk Sues Hims & Hers Over Semaglutide Patent
Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of breaching its U.S. patent on semaglutide used in blockbuster obesity drugs like Ozempic and Wegovy. Despite Hims scrapping plans for a copycat Wegovy pill, Novo claims the compounded versions remain dangerous and infringing. This legal battle highlights growing tensions over compounded GLP-1 drugs post-shortage.
5 min read
GLP-1 Pancreatitis Risk: MHRA Warning and Patient Guide
The UK's MHRA has updated guidance on a small but serious risk of acute pancreatitis linked to popular GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro. With over 1.6 million users, understanding symptoms and reporting is crucial. This guide breaks down the latest data, risks, and management strategies.
4 min read
Wegovy Recall: Hair in Syringes, Gold Star Droppings Issue
Novo Nordisk recalled Wegovy pens after FDA inspectors found hair particles in prefilled syringes. Gold Star Distribution issued a broad recall due to rodent feces and droppings in storage. These Class II recalls highlight contamination risks in GLP-1 medications and pharma supply chains.
3 min read